Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
126.8 GBX 0.60 ( 0.48%)
Last update at 2026-10-27T16:35:00Z
VOLUME
135144
Market Cap
533.39M

Momentum Score

…

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
126.60
Low
128.80
High
52 Week Price Range
79.60
Low
102.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
126.20
Dividend Yield
-
Revenue TTM
-67.18M
Revenue Per Share
-0.11
Gross Profit TTM
-67.18M
Debt / Equity
-
ROE
-8.64%
Net Debt
-1.11M
ROCE
-11.60%
Diluted EPS TTM
-0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -143.16M 3.79M -56.02M 8.84M 53.16M
Net income -143.16M 3.79M -56.02M 8.84M 53.16M
Selling general administrative 3.28M 22.61M 2.88M 2.53M 2.29M
Selling and marketing expenses - 19.11M - - -
Gross profit -68.31M 14.10M -39.79M 3.68M 66.42M
Ebit - 8.14M -56.02M 8.84M 53.16M
Ebitda -143.16M 3.79M -4.63M -4.25M -4.71M
Depreciation and amortization - -4.35M 51.38M -13.09M -57.87M
Operating income -143.16M 8.14M -51.38M 13.09M 57.87M
Other operating expenses 74.85M 22.61M 16.23M 9.86M 25.38M
Interest expense - - - 0.00M 0.00M
Income tax expense - -0.56M -4.63M -4.25M -4.71M
Total revenue -68.31M 30.75M -39.79M 18.69M 78.54M
Total operating expenses 74.85M 22.61M 32.04M 24.87M 37.50M
Cost of revenue - 16.64M - 15.01M 12.12M
Total other income expense net - -4.35M -4.63M -4.25M -4.71M
Net income from continuing ops -143.16M 3.79M -56.02M 8.84M 53.16M
Net income applicable to common shares - - -56.02M 8.84M 53.16M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 1064.88M 1251.10M 1268.41M 1333.39M 1338.41M
Other current assets 0.07M 0.07M - - -
Total liab 11.79M 12.22M 13.76M 23.55M 38.12M
Total stockholder equity 1053.08M 1238.88M 1254.65M 1309.84M 1300.29M
Other current liab - 16.96M 7.30M 9.39M 8.84M
Common stock 768.00M 768.00M 768.00M 768.00M 768.00M
Capital stock 768.00M 768.00M 768.00M 768.00M 768.00M
Retained earnings - 491.10M 486.66M 541.84M 532.29M
Other liab - - - 8.46M 23.50M
Other assets - 0.07M 0.17M 0.17M 0.00M
Cash 1.11M 0.26M 0.01M 0.28M 0.01M
Total current liabilities - 16.96M 13.76M 15.09M 14.61M
Net debt -1.11M -0.26M -0.01M -0.28M -0.01M
Other stockholder equity 285.08M -20.22M -1254.65M -1309.84M -1300.29M
Total current assets 9.92M 9.40M 10.15M 10.15M 10.46M
Long term investments 1054.95M 1241.70M 1258.26M 1323.23M 1327.95M
Net tangible assets - - 1254.65M 1309.84M 1300.29M
Net receivables 8.74M 9.07M 10.07M 9.71M 10.45M
Accounts payable - - 6.46M 5.70M 5.78M
Accumulated other comprehensive income - 0.00M - - -
Common stock total equity - - - - 768.00M
Non currrent assets other 1054.95M -1241.70M -1258.26M -1323.23M -1327.95M
Non current assets total 1054.95M 1241.70M 1258.26M 1323.23M 1327.95M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments - - - - 0.00M
Change to liabilities - - 0.00M -0.08M 0.39M
Total cash from financing activities -43.06M -20.22M - - -13.25M
Change to operating activities - - 0.50M 0.50M 0.50M
Net income -143.16M 3.79M -56.02M 8.84M 53.16M
Change in cash 0.85M 0.25M -0.27M 0.26M -0.00M
Begin period cash flow 0.26M 0.01M 0.28M 0.01M 0.02M
End period cash flow 1.11M 0.26M 0.01M 0.28M 0.01M
Total cash from operating activities 43.91M 20.47M -0.27M 0.26M -0.00M
Dividends paid - - - - 13.25M
Change to account receivables 0.33M 1.00M -0.27M 0.57M -1.31M
Sale purchase of stock -43.06M -20.22M - - -
Change to netincome - - 55.26M -9.07M -52.23M
Capital expenditures 43.91M 0.00M 0.00M 0.00M 0.00M
Change in working capital -1.01M 2.14M 0.50M 0.49M -0.93M
Stock based compensation - -3.85M -12.03M -15.76M 10.56M
Other non cash items 188.08M 18.39M 67.29M 6.70M -62.79M
Free cash flow 43.91M 20.47M -0.27M 0.26M -0.00M

Peer Comparison*

Sector: Financial Services Industry: Asset Management

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
SYNC
Syncona Limited
0.60
0.48%
126.80 - - 4.07 0.53 14.00
MNTN
Schiehallion Fund Ltd
-0.01
0.46%
2.18 0.05 - 4.35 1.25 5.65
BHMU
BH Macro Limited
-
-%
4.29 0.09 - 39.01 0.71 6.47
TFG
Tetragon Financial Group Ltd
0.15
1.00%
15.10 0.02 7.04 1.16 0.31 2.06
BPCR
BioPharma Credit PLC
0.00
0.41%
0.98 0.09 - 6.73 0.91 7.95

Profile*

Syncona Limited

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.

2nd Floor, London, United Kingdom, WC1B 3SR

44 20 3981 7909

1215

Name Title Year Born
Mr. Thomas Henderson Co-Founder & Non-Exec. Director 1966
Dr. Martin Patrick Murphy Ph.D. Chief Exec. Officer 1968
Mr. John McDonald Co-Founder 1965
Mr. Rolf Kristian Berndtson Soderstrom ACA, BA Chief Financial Officer 1966
Dr. Christopher J. Hollowood Ph.D. CIO & Managing Partner of Syncona Investment Management Ltd. 1975
Ms. Annabel Clay Head of Investor Relations NA
Mr. Andrew Cossar Gen. Counsel of Syncona Investment Management Ltd. NA
Ms. Fenella Dernie Exec. Officer NA
Mr. Edward Eliot Hodgkin DPhil Sr. Partner 1963
Ms. Nikki Padden Ph.D. Head of Fin. at Syncona Investment Management Ltd. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…